On July 22, 2024, HOOKIPA Pharma Inc. announced significant leadership changes, including the departure of Joern Aldag as Chief Executive Officer and Reinhard Kandera as Chief Financial Officer. Aldag and Kandera also resigned from their positions as directors of the company. Their resignations were not due to any disagreements with the company's operations, policies, or practices. They will receive compensation consistent with their employment agreements. Malte Peters, M.D., was appointed as the new CEO and President, effective immediately, and will continue to serve as a Class II director until the 2027 annual meeting of stockholders. Terry Coelho was appointed as the Executive Vice President and Chief Financial Officer, also effective immediately, and will continue to serve as a Class III director...Show More

On July 22, 2024, HOOKIPA Pharma Inc. announced significant leadership changes, including the departure of Joern Aldag as Chief Executive Officer and Reinhard Kandera as Chief Financial Officer. Aldag and Kandera also resigned from their positions as directors of the company. Their resignations were not due to any disagreements with the company's operations, policies, or practices. They will receive compensation consistent with their employment agreements. Malte Peters, M.D., was appointed as the new CEO and President, effective immediately, and will continue to serve as a Class II director until the 2027 annual meeting of stockholders. Terry Coelho was appointed as the Executive Vice President and Chief Financial Officer, also effective immediately, and will continue to serve as a Class III director until the 2025 annual meeting. Coelho stepped down from her roles on the Audit and Compensation Committees upon her appointment. Sean A. Cassidy was appointed as an independent Class III director and will serve as the chair of the Audit Committee and a member of the Compensation Committee. The company also approved a special retainer for Julie O'Neill as a member of the Strategic Committee and appointed her to the Compensation Committee. These leadership changes are part of HOOKIPA's strategic review to enhance focus on its lead oncology candidate, HB-200, and to create shareholder value. The company is conducting a review of its business operations and strategy, which will not affect its ongoing operations or clinical trials.